Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
Fear of another viral outbreak is generating a lot of buzz around these three biotech stocks.
Investors are furious about management's plan to sell its most valuable asset in order to chase a lackluster oncology program.
No podcast episodes available.
CMRX earnings call for the period ending June 30, 2022.
CMRX earnings call for the period ending March 31, 2022.
CMRX earnings call for the period ending December 31, 2021.
CMRX earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.